Boston Scientific Co. (NYSE:BSX) Shares Bought by SVB Wealth LLC

SVB Wealth LLC raised its stake in Boston Scientific Co. (NYSE:BSX) by 12.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,051 shares of the medical equipment provider’s stock after acquiring an additional 1,503 shares during the period. SVB Wealth LLC’s holdings in Boston Scientific were worth $812,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in BSX. International Assets Investment Management LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at about $54,000. Acadian Asset Management LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at about $35,000. Prudential PLC purchased a new stake in shares of Boston Scientific in the first quarter valued at about $1,076,000. Cetera Investment Advisers raised its holdings in shares of Boston Scientific by 24.0% in the first quarter. Cetera Investment Advisers now owns 28,793 shares of the medical equipment provider’s stock valued at $1,275,000 after buying an additional 5,581 shares during the last quarter. Finally, Sequoia Financial Advisors LLC purchased a new stake in shares of Boston Scientific in the first quarter valued at about $230,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the sale, the executive vice president now directly owns 56,508 shares in the company, valued at $3,779,820.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Edward J. Ludwig sold 7,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the sale, the director now owns 41,374 shares in the company, valued at $2,690,551.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the sale, the executive vice president now owns 56,508 shares in the company, valued at approximately $3,779,820.12. The disclosure for this sale can be found here. Insiders have sold 50,979 shares of company stock worth $3,418,529 over the last ninety days. 0.50% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BSX. JPMorgan Chase & Co. upped their target price on shares of Boston Scientific from $60.00 to $72.00 and gave the company an “overweight” rating in a report on Thursday, February 1st. Mizuho raised shares of Boston Scientific from a “neutral” rating to a “buy” rating and increased their price target for the stock from $65.00 to $80.00 in a report on Thursday, February 1st. Citigroup increased their price target on shares of Boston Scientific from $71.00 to $79.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. BTIG Research reissued a “buy” rating and set a $64.00 price target on shares of Boston Scientific in a report on Friday, December 29th. Finally, Wells Fargo & Company increased their price target on shares of Boston Scientific from $70.00 to $72.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Two analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $68.50.

Boston Scientific Trading Down 0.1 %

Shares of Boston Scientific stock opened at $67.33 on Friday. The company has a 50-day moving average of $67.25 and a two-hundred day moving average of $59.84. The stock has a market cap of $98.78 billion, a PE ratio of 62.93, a price-to-earnings-growth ratio of 2.38 and a beta of 0.78. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $69.21. The company has a current ratio of 1.32, a quick ratio of 0.82 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. The business had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same period in the prior year, the business earned $0.45 earnings per share. On average, research analysts anticipate that Boston Scientific Co. will post 2.25 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.